AKT3

Across TCGA pan-cancer cohorts, AKT3 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of AKT3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where AKT3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AKT3 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where AKT3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AKT3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.696	<.001	9	view →
LSCC	Male	III,IV	−0.679	<.001	8	view →
PDAC	All	All	+0.300	.001	4	view →
OV	All	All	−1.011	.012	2	view →
COAD	Male	II,III,IV	−0.925	.008	2	view →
CCRCC	All	All	+0.134	.001	2	view →
HNSC	All	II,III,IV	−0.171	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

AKT3–LUAD

Open the LUAD breakdown →